Trogarzo (Ibalizumab-uiyk)

Last Review Date: May 1st, 2018  Number: MG.MM.PH.50v2

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, (“EmblemHealth”) has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions

Trogarzo (Ibalizumab-uiyk), a recombinant humanized monoclonal antibody, blocks HIV-1 from infecting CD4+ T cells by binding to domain 2 of CD4 and interfering with post-attachment steps required for the entry of HIV-1 virus particles into host cells and preventing the viral transmission that occurs via cell-cell fusion. Trogarzo (Ibalizumab-uiyk), in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.

Dosing

Administer intravenously as a single loading dose of 2,000 mg followed by a maintenance dose of 800 mg every 2 weeks.

Guideline

Trogarzo (Ibalizumab-uiyk) is considered medically necessary for the treatment of HIV-1 infection when the following criteria are met:

- Patient is 18 years of age or older; AND
- Patient is diagnosed with HIV-1 infection; AND
- Patient has a documented baseline viral load of greater than 1,000 copies/ml; AND
- Patient must have been treated with antiretrovirals for at least 6 months and be failing or had recently failed (i.e., in the last 8 weeks) therapy; AND
• Documented resistance to ONE antiretroviral medication from each of the following three classes of antiretroviral medications:
  o Protease inhibitor (PI)
  o Nucleoside reverse transcriptase inhibitor (NRTI)
  o Non-nucleoside reverse transcriptase inhibitor (NNRTI)); AND
• Patient will be using Trogarzo in combination with antiretroviral treatment drugs.

Coverage for Trogarzo (ibalizumab-uiyk) may be renewed when the following criteria are met:
• Patient demonstrates a decreased viral load indicating clinically significant disease response and improvement to achieve <200 copies/mL; AND
• Absence of unacceptable toxicity from the drug (i.e. immune reconstitution inflammatory syndrome (IRIS), etc.)

Limitations/Exclusions
• Initial approval will be granted for 6 months and may be renewed
• Renewed approvals will be granted for 6 months

Revisions
12/3/2018 – Added J1746 and removed J3590 from Applicable Procedure Codes.

Applicable Procedure Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J1746</td>
<td>Injection, ibalizumab-uiyk, 10mg</td>
</tr>
</tbody>
</table>

Applicable Diagnosis Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>B20</td>
<td>Human immunodeficiency virus (HIV) disease</td>
</tr>
</tbody>
</table>

References
1. TROGARZO [package insert], Montreal, Quebec Canada; Theratechnologies; 2018.